ApoIII and the treatment and diagnosis of diabetes
AssigneeBioCrine AB
InventorPer-Olof Berggren
Life of this patent
Estimating the term…
Abstract
The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells.
Claims4
A method for diagnosing Type 1 diabetes in a subject, comprising:
- (a) measuring an amount of sialylated apoCIII in a blood serum sample from the subject;
- (b) comparing the amount of sialylated apoCIII measured in step (a) with an amount of sialylated apoCIII in a control blood serum sample;
- and
- (c) diagnosing those subjects with an elevated amount of sialylated apoCIII measured in step (a) relative to the amount of sialylated apoCIII in the control blood serum sample as having Type 1 diabetes.
Dependencies are inferred from the claim text.